Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Capecitabine |
| Synonyms | |
| Therapy Description |
Xeloda (capecitabine) is an antimetabolite that when activated to 5-FU ultimately inhibits DNA synthesis and cell division (NCI Drug Dictionary). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Capecitabine | Xeloda | R340 | Chemotherapy - Antimetabolite 14 | Xeloda (capecitabine) is an antimetabolite that when activated to 5-FU ultimately inhibits DNA synthesis and cell division (NCI Drug Dictionary). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02483247 | Phase Ib/II | Paclitaxel Doxorubicin Capecitabine Nivolumab Sunitinib Pembrolizumab Amcasertib | A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer | Completed | USA | CAN | 0 |
| NCT03322215 | Phase II | Capecitabine Fulvestrant + Palbociclib | HR+/HER2- Advanced Breast Cancer and Endocrine Resistance (PASIPHAE) | Terminated | SWE | GBR | 0 |
| NCT06646445 | Phase II | Pembrolizumab Capecitabine + Oxaliplatin Capecitabine Fluorouracil Fluorouracil + Oxaliplatin | Neoadjuvant Pembrolizumab with a Watch-and-wait Strategy for Patients with DMMR/MSI-H Localized Colon Cancer: GERCOR G-109 PRODIGE 84 PREMICES Phase II Trial (PREMICES) | Not yet recruiting | FRA | 0 |
| NCT02715531 | Phase I | Capecitabine Atezolizumab + Cisplatin + Fluorouracil Atezolizumab + Gemcitabine + Nab-paclitaxel Atezolizumab + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Bevacizumab Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin | A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors | Completed | USA | NZL | AUS | 4 |
| NCT02555657 | Phase III | Pembrolizumab Eribulin Gemcitabine Vinorelbine Capecitabine | Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) | Completed | 0 | |
| NCT03136406 | Phase Ib/II | GI-4000 Leucovorin Avelumab Nab-paclitaxel Bevacizumab Cyclophosphamide Capecitabine Oxaliplatin Fluorouracil ETBX-011 Nogapendekin alfa inbakicept | QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | Terminated | USA | 0 |
| NCT03487666 | Phase II | Capecitabine + Nivolumab Capecitabine Nivolumab | OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease | Active, not recruiting | USA | 0 |
| NCT02244489 | Phase I | Capecitabine Oxaliplatin Momelotinib | Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma | Terminated | USA | 0 |
| NCT04595565 | Phase III | Sacituzumab govitecan-hziy Cisplatin Carboplatin Capecitabine | Sacituzumab Govitecan in Primary HER2-negative Breast Cancer (SASCIA) | Active, not recruiting | IRL | FRA | ESP | DEU | CHE | BEL | AUT | 0 |
| NCT02042443 | Phase II | Fluorouracil + Leucovorin Capecitabine Trametinib | Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery | Completed | USA | 0 |
| NCT01828554 | Phase III | Capecitabine | Capecitabine Pharmacokinetics(PK)-Actual Versus Ideal Body Weight | Completed | USA | 0 |
| NCT03300609 | Phase III | Capecitabine Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab Fluorouracil + Leucovorin + Panitumumab | 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab | Terminated | USA | 0 |
| NCT02120417 | Phase II | Capecitabine + Ruxolitinib Capecitabine | A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer | Terminated | USA | ITA | GBR | FRA | ESP | 1 |
| NCT03387098 | Phase Ib/II | GI-4000 Leucovorin Nab-paclitaxel Bevacizumab Avelumab Nogapendekin alfa inbakicept Fluorouracil ETBX-011 Oxaliplatin Aldoxorubicin Capecitabine Cyclophosphamide | QUILT-3.070: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | Terminated | USA | 0 |
| NCT02000622 | Phase III | Olaparib Vinorelbine Eribulin Capecitabine | Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (OlympiAD) | Active, not recruiting | USA | TUR | ROU | POL | ITA | HUN | GBR | FRA | ESP | CZE | CHE | BGR | 7 |
| NCT03783442 | Phase III | Cisplatin Paclitaxel Tislelizumab Oxaliplatin Fluorouracil Capecitabine | A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | Completed | USA | ROU | POL | ITA | GBR | FRA | ESP | DEU | CZE | BEL | AUS | 5 |
| NCT02981342 | Phase II | Capecitabine Abemaciclib Gemcitabine Abemaciclib + LY3023414 Abemaciclib + Galunisertib | A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma | Completed | USA | ISR | GBR | FRA | ESP | BEL | AUS | 1 |
| NCT06245889 | Phase II | Cyclophosphamide Olaparib Carboplatin + Paclitaxel + Pembrolizumab Doxorubicin Capecitabine | PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC (NeoADAPT) | Recruiting | USA | 0 |
| NCT04895358 | Phase III | Nab-paclitaxel Nab-paclitaxel + Pembrolizumab Capecitabine + Pembrolizumab Paclitaxel + Pembrolizumab Capecitabine Pegylated liposomal doxorubicin Paclitaxel Pegylated liposomal doxorubicin + Pembrolizumab | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) | Active, not recruiting | USA | TUR | SWE | ROU | POL | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CAN | BRA | AUT | AUS | ARG | 11 |
| NCT02494583 | Phase III | Capecitabine Cisplatin + Fluorouracil Pembrolizumab | Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) | Completed | 0 | |
| NCT03734029 | Phase III | Trastuzumab deruxtecan Nab-paclitaxel Capecitabine Paclitaxel Gemcitabine Eribulin | Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] | Active, not recruiting | USA | SWE | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUT | 6 |
| NCT02117479 | Phase III | Ruxolitinib Capecitabine | Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1) | Terminated | USA | NZL | ITA | GBR | ESP | DEU | CAN | BEL | AUS | 3 |
| NCT02688712 | Phase II | Capecitabine + Galunisertib Fluorouracil + Galunisertib Galunisertib Fluorouracil Capecitabine | ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer | Active, not recruiting | USA | 0 |
| NCT04494425 | Phase III | Capecitabine Nab-paclitaxel Trastuzumab deruxtecan Paclitaxel | Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer (DB-06) | Active, not recruiting | USA | SWE | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CAN | BRA | BEL | AUT | AUS | ARG | 10 |
| NCT01213238 | Phase I | Oxaliplatin Capecitabine Bevacizumab | Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab | Completed | USA | 0 |
| NCT01921751 | Phase II | Gemcitabine + Nab-paclitaxel Capecitabine | High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery | Terminated | USA | 0 |
| NCT03721744 | Phase II | Gemcitabine + Napabucasin + Paclitaxel Fluorouracil + Liposomal irinotecan Gemcitabine Fluorouracil Capecitabine | A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer | Recruiting | FRA | ESP | 1 |
| NCT04428151 | Phase II | Lenvatinib + Pembrolizumab Docetaxel Paclitaxel Capecitabine Cetuximab Lenvatinib | Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) | Active, not recruiting | USA | ROU | NOR | ISR | GBR | FRA | ESP | DNK | CAN | BRA | AUS | 4 |
| NCT03901339 | Phase III | Eribulin Gemcitabine Vinorelbine Capecitabine Sacituzumab govitecan-hziy | Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer (TROPiCS-02) | Completed | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | 0 |
| NCT01997333 | Phase II | Glembatumumab vedotin Capecitabine | Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 0 |
| NCT05238831 | Phase II | Vemurafenib Vinorelbine Palbociclib Irinotecan Alpelisib Capecitabine Atezolizumab Paclitaxel Entrectinib Cobimetinib Nab-paclitaxel Fulvestrant Carboplatin Olaparib Pertuzumab/trastuzumab/hyaluronidase-zzxf Niraparib Vismodegib Alectinib Letrozole Ado-trastuzumab emtansine Bevacizumab Eribulin Anastrozole | SMMART Adaptive Clinical Treatment (ACT) Trial | Withdrawn | 0 | |
| NCT02314117 | Phase III | Capecitabine Fluorouracil Cisplatin Ramucirumab | A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer | Completed | USA | POL | NLD | ITA | ISR | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BEL | ARG | 4 |
| NCT05704985 | Phase I | DK210 DK210 + Nivolumab Paclitaxel DK210 + Pembrolizumab Oxaliplatin Capecitabine Fluorouracil Carboplatin | Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors | Recruiting | USA | 0 |
| NCT01945775 | Phase III | Gemcitabine Capecitabine Vinorelbine Talazoparib Eribulin | A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (EMBRACA) | Completed | USA | POL | ITA | ISR | IRL | GBR | FRA | ESP | DEU | BRA | BEL | AUS | 4 |
| NCT06312176 | Phase III | Paclitaxel Capecitabine Pegylated liposomal doxorubicin Nab-paclitaxel Sacituzumab govitecan-hziy Pembrolizumab + Sacituzumab govitecan-hziy | A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) | Recruiting | USA | ROU | POL | NZL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | CHE | CAN | BRA | BEL | AUS | ARG | 12 |
| NCT03424005 | Phase Ib/II | Atezolizumab + Bevacizumab + Selicrelumab Atezolizumab + RO6874281 Atezolizumab + Bevacizumab Atezolizumab + Carboplatin + Gemcitabine Atezolizumab + Eribulin Capecitabine Atezolizumab Atezolizumab + Bevacizumab + Cobimetinib Atezolizumab + Capecitabine Atezolizumab + Ipatasertib Atezolizumab + Ladiratuzumab vedotin | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC) (Morpheus-TNBC) | Recruiting | USA | ISR | GBR | FRA | ESP | DEU | AUS | 1 |
| NCT03355157 | FDA approved | Exemestane + Palbociclib Tamoxifen Paclitaxel Exemestane Capecitabine Palbociclib + Tamoxifen Epirubicin Vinorelbine Fulvestrant + Palbociclib Fulvestrant Letrozole Letrozole + Palbociclib | A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study). (PADMA) | Completed | DEU | 0 |
| NCT05104866 | Phase III | Gemcitabine Capecitabine Datopotamab deruxtecan Vinorelbine Eribulin | A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) | Active, not recruiting | USA | POL | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CAN | BRA | BEL | ARG | 7 |
| NCT03872388 | Phase II | Atorvastatin + Capecitabine Capecitabine | Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy | Terminated | USA | 0 |
| NCT05249101 | Phase Ib/II | Capecitabine Capecitabine + CG200745 | A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma | Recruiting | USA | 0 |
| NCT02119663 | Phase III | Capecitabine Capecitabine + Ruxolitinib | A Study of Ruxolitinib in Pancreatic Cancer Patients | Terminated | USA | SWE | NLD | ISR | IRL | FRA | DNK | CHE | AUT | 5 |
| NCT04333706 | Phase Ib/II | Capecitabine Capecitabine + Sarilumab | A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) (EMPOWER) | Recruiting | USA | 0 |
| NCT06018337 | Phase III | Nab-paclitaxel Paclitaxel DB-1303 Capecitabine | A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) | Recruiting | USA | POL | ITA | HUN | GBR | FRA | CAN | BEL | AUS | 3 |
| NCT02297230 | Phase Ib/II | Capecitabine Paclitaxel Paclitaxel + Trastuzumab | Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics | Terminated | USA | 0 |
| NCT03512756 | Phase II | Methoxsalen + Phenytoin + Sirolimus + SM88 Gemcitabine Fluorouracil Capecitabine | A Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer | Terminated | USA | 0 |
| NCT05840211 | Phase III | Paclitaxel Capecitabine Nab-paclitaxel Sacituzumab govitecan-hziy | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy (ASCENT-07) | Active, not recruiting | USA | POL | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 11 |
| NCT02492711 | Phase III | Vinorelbine Capecitabine Gemcitabine Trastuzumab Eribulin Margetuximab-cmkb | Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer | Completed | USA | POL | NLD | ITA | ISR | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BEL | AUT | 3 |
| NCT03770689 | Phase Ib/II | Capecitabine Capecitabine + Peposertib | Phase Ib/II Study of M3814 in Combination With Capecitabine and Radiotherapy in Rectal Cancer | Completed | USA | ESP | 0 |
| NCT03387111 | Phase Ib/II | Capecitabine Nab-paclitaxel Leucovorin GI-6301 GI-6207 Avelumab ETBX-021 ETBX-051 ETBX-061 Aldoxorubicin Cisplatin Cyclophosphamide Bevacizumab Necitumumab GI-4000 Cetuximab Nogapendekin alfa inbakicept Fluorouracil ETBX-011 | Molecularly Informed Integrated Immunotherapy Combining Innate haNK Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With SCC Who Have Progressed on or After Platinum-based Chemotherapy and Anti- PD-1/ PD-L1 Therapy | Terminated | USA | 0 |
| NCT02229149 | Phase II | Paclitaxel Docetaxel Pertuzumab + Trastuzumab Nab-paclitaxel Vinorelbine Trastuzumab Capecitabine | Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer | Terminated | USA | 0 |
| NCT01729923 | Phase II | Capecitabine Celecoxib | A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer | Terminated | USA | 0 |
| NCT02451553 | Phase I | Afatinib Capecitabine | Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer | Completed | USA | 0 |
| NCT02305186 | Phase Ib/II | Pembrolizumab Capecitabine | Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer | Unknown status | USA | 0 |
| NCT06409390 | Phase I | Fulvestrant + Ribociclib Trastuzumab deruxtecan Sacituzumab govitecan-hziy Capecitabine Abemaciclib + Fulvestrant Cyclophosphamide + Docetaxel + Sargramostim | Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer | Recruiting | USA | 0 |
| NCT06099769 | Phase II | Capecitabine Paclitaxel Enzalutamide Enzalutamide + Mifepristone Eribulin Carboplatin | A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer | Recruiting | USA | 0 |
| NCT06112379 | Phase III | Carboplatin + Paclitaxel Cyclophosphamide + Epirubicin + Paclitaxel Capecitabine Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel Cyclophosphamide + Doxorubicin + Pembrolizumab Cyclophosphamide + Epirubicin + Pembrolizumab Datopotamab deruxtecan + Durvalumab Cyclophosphamide + Doxorubicin + Paclitaxel Carboplatin + Paclitaxel + Pembrolizumab | A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer | Recruiting | USA | TUR | POL | ITA | HUN | GBR | FRA | ESP | DEU | CHE | CAN | BRA | BGR | BEL | AUT | AUS | 10 |
| NCT06109779 | Phase III | AZD2936 + Cisplatin + Gemcitabine AZD2936 + Tegafur-gimeracil-oteracil Potassium AZD2936 + Capecitabine Capecitabine Tegafur-gimeracil-oteracil Potassium Cisplatin + Gemcitabine | A Study of Rilvegostomig Plus Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Bil01) | Recruiting | USA | TUR | POL | NOR | ITA | GBR | FRA | ESP | DNK | DEU | CAN | BRA | BEL | AUS | 7 |
| NCT03387085 | Phase Ib/II | ETBX-051 Aldoxorubicin ETBX-061 Cisplatin Cyclophosphamide haNK cells GI-4000 Bevacizumab Nogapendekin alfa inbakicept Fluorouracil ETBX-011 Oxaliplatin Capecitabine Leucovorin GI-6301 Nab-paclitaxel Avelumab GI-6207 | QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. | Terminated | USA | 0 |
| NCT02678182 | Phase II | Durvalumab Rucaparib Capecitabine Trastuzumab Capecitabine + Ramucirumab | Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial (PLATFORM) | Active, not recruiting | GBR | 0 |
| NCT02083653 | Phase II | SYM004 Fluorouracil Capecitabine | Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer | Completed | USA | POL | ITA | HUN | FRA | ESP | DEU | BEL | AUT | 1 |
| NCT04188145 | Phase III | Capecitabine Fluorouracil + Leucovorin Bevacizumab Bevacizumab + Fluorouracil + Leucovorin Bevacizumab + Capecitabine | A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer (BEVAMAINT) | Recruiting | FRA | 0 |
| NCT02921256 | Phase II | Veliparib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Capecitabine + Veliparib Capecitabine | Veliparib and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer | Completed | USA | 1 |
| NCT01497392 | Phase I | Gemcitabine Dovitinib Capecitabine | Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers | Completed | USA | 0 |
| NCT05062317 | Phase II | Capecitabine Leucovorin Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin | Risk-Stratified Adjuvant Therapy: ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases | Recruiting | USA | 0 |
| NCT03093870 | Phase II | Capecitabine + Varlitinib Capecitabine | Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer | Completed | USA | POL | HUN | ESP | AUS | 6 |
| NCT03326674 | Phase III | Capecitabine Capecitabine + Tesetaxel | Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC (CONTESSA) | Terminated | USA | POL | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUT | AUS | 6 |
| NCT03818685 | Phase II | Ipilimumab + Nivolumab Capecitabine | Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease (BreastImmune03) | Active, not recruiting | FRA | 0 |
| NCT05374512 | Phase III | Eribulin Nab-paclitaxel Paclitaxel Datopotamab deruxtecan Carboplatin Capecitabine | A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy | Active, not recruiting | USA | TUR | POL | ITA | HUN | GBR | FRA | ESP | DEU | CAN | BRA | BEL | ARG | 10 |
| NCT05288777 | Phase II | Capecitabine Ado-trastuzumab emtansine | Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer (Breast53) | Recruiting | USA | 0 |
| NCT02178644 | Phase I | YIV-906 Capecitabine | Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer | Completed | USA | 0 |
| NCT04849364 | Phase II | Capecitabine + Inavolisib Atezolizumab + Capecitabine Capecitabine + Talazoparib Capecitabine Atezolizumab + Capecitabine + Talazoparib | Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer (PERSEVERE) | Active, not recruiting | USA | 0 |
| NCT01061515 | Phase I | Capecitabine Bevacizumab Oxaliplatin | Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer | Active, not recruiting | USA | 0 |
| NCT02009449 | Phase I | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel | A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
| NCT04158362 | Phase III | Capecitabine Abemaciclib + Fulvestrant Abemaciclib + Letrozole Paclitaxel Abemaciclib + Anastrozole | Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer (AMBRE) | Active, not recruiting | FRA | 0 |
| NCT05200988 | Phase II | Mitomycin C Ipilimumab + Nivolumab Capecitabine Fluorouracil | Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC (Indi-Blade) | Active, not recruiting | NLD | 0 |
| NCT04711824 | Phase Ib/II | Nab-paclitaxel Carboplatin + Gemcitabine Cisplatin Durvalumab + Olaparib Paclitaxel Capecitabine Gemcitabine Carboplatin Eribulin | Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases (SOLARA) | Recruiting | USA | 0 |
| NCT04124601 | Phase II | Capecitabine Capecitabine + Ipilimumab + Nivolumab | Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer (CHINOREC) | Completed | AUT | 0 |
| NCT03921684 | Phase II | Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin Capecitabine | Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients | Recruiting | ISR | 0 |
| NCT02423954 | Phase Ib/II | Temsirolimus Nivolumab Capecitabine Irinotecan | Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus) | Terminated | USA | 0 |
| NCT03383679 | Phase II | Darolutamide Capecitabine | Study on Androgen Receptor and Triple Negative Breast Cancer (START) | Completed | FRA | 0 |
CKB BOOST